Printer Friendly

MEDCO RESEARCH REPORTS TRANSITION PERIOD FINANCIAL RESULTS

 LOS ANGELES, Feb. 9 /PRNewswire/ -- Medco Research, Inc. (AMEX: MRE) today announced operating results for the "transition period" of Sept. 1, 1992 through Dec. 31, 1992. Medco had previously reported that it was changing its reporting period from a fiscal year ending August 31 to a calendar year basis with the first calendar year commencing Jan. 1, 1993.
 Revenues, including investment income and gains, increased to $2,814,022 in the four month period from $1,522,914 in the corresponding year-earlier period, while total costs and expenses increased to $2,790,059 from $1,110,293, reflecting the planned acceleration of research and development costs and the recruitment of additional scientific, administrative and support personnel. Net income for the period amounted to $20,763, a fraction of a cent a share on 11.3 million average shares outstanding, as compared to $372,421, $.04 a share on 9.6 million average shares outstanding, for the comparable period of the prior year.
 Commenting on the results, Medco Chief Executive Officer, Archie W. Prestayko, noted that, "Adenocard sales in the United States by our North American licensee, Fujisawa USA, Inc., were $7.2 million in the transition period, up from $5.9 million in the year-earlier period. As planned, our research and developments costs increased to $1,038,751 for the four month period as compared to $111,480 in the comparable prior year period. The additional expenses supported, among other programs, the Phase II clinical trial of IPPA, a nuclear imaging agent used in the detection of metabolic activity in hibernating heart muscle, and our Phase I study of ATP in cancer patients."
 Medco Research is a pharmaceutical company engaged in the acquisition, research and development of new prescription drugs for the diagnosis or treatment of certain cardiovascular diseases and cancer.
 -0- 2/9/93
 /CONTACT: Archie W. Prestayko, Ph.D. of Medco Research, Inc., 213-966-4148; or Fredric J. Spar of Kekst and Company, 212-593-2655, for Medco Research, Inc./
 (MRE)


CO: Medco Research, Inc. ST: California IN: MTC SU: ERN

LR -- NY001 -- 4472 02/09/93 08:55 EST
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Feb 9, 1993
Words:349
Previous Article:FIRST MORTGAGE CONTINUES RECORD GROWTH IN THIRD QUARTER, NINE MONTHS; REPORTS HIGHER REVENUES, INCOME FROM ALL OPERATIONS
Next Article:APPLE INTRODUCES COLOR TO ITS AWARD-WINNING POWERBOOK LINE
Topics:


Related Articles
MEDCO RESEARCH REPORTS FIRST QUARTER FINANCIAL RESULTS
MEDCO RESEARCH REPORTS SECOND QUARTER FINANCIAL RESULTS
MEDCO RESEARCH REPORTS YEAR END FINANCIAL RESULTS
MEDCO RESEARCH REPORTS THIRD QUARTER RESULTS
MEDCO RESEARCH REPORTS FOURTH QUARTER AND YEAR-END FINANCIAL RESULTS
MEDCO RESEARCH REPORTS FIRST-QUARTER RESULTS
MEDCO RESEARCH REPORTS SECOND-QUARTER RESULTS
MEDCO RESEARCH REPORTS THIRD-QUARTER RESULTS
MEDCO RESEARCH REPORTS PROFITABILITY FOR FIRST QUARTER 1996
Medco Research Reports Earnings of $0.09 For The Fourth Quarter And $0.40 For The Year 1996

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters